Charles River sees 2026 revenue, non-GAAP EPS at upper end of prior guidance ranges
CRL•Charles River reaffirmed its 2026 guidance, projecting organic revenue growth near 1% and non-GAAP EPS near $11.45, both at the upper ends of prior ranges. It also introduced 2027-2030 targets, including 5%-7% organic revenue CAGR and a non-GAAP operating margin near 24%.
1. 2026 outlook reaffirmed
Charles River expects 2026 organic revenue growth near 1%, within its 0%-1% range, and a non-GAAP operating margin of 21.0%-21.3%. It forecast non-GAAP EPS near $11.45, the upper end of its $11.15-$11.45 range, citing continued favorable biopharma client demand. The company also set 2027-2030 targets for 5%-7% organic revenue CAGR, a non-GAAP operating margin near 24%, and low-double-digit non-GAAP EPS CAGR; its Create the Future program aims to generate more than $300 million in savings over that period.
